This Week in Cell and Gene Therapy: 14 New Developments to Know (June 27, 2022)

In Vitro Diagnostics Business Outlook: Blood Typing Has Rebounded

In 2021, the world market for blood grouping and blood typing rebounded from a 3.2% decline in 2020 due to COVID-19 impacts, reaching an estimated $945 million in revenues, according to an upcoming issue of the In Vitro Diagnostics Business Outlook. The overall market is expected to stabilize in 2022 and grow at a 1% […]

This Week in Cell and Gene Therapy: 12 New Developments to Know (June 13, 2022)

The Middle East and Africa Region a $4 Billion Hotbed for IVD Investment

Globally, in vitro diagnostic (IVD) companies are exploring opportunities in developing countries, where rising incomes and standards of living have sparked a new health consciousness and growing demands for quality medical care.  As the COVID-19 dust settles, it is expected that the interest in geographic expansion will once again return to the Middle East and […]

Single Cell Genomics in Next-Generation Sequencing (NGS) Market Reaches $780 Million

VIDEO: 5 Key Facts about Point-of-Care (POC) Diagnostic Tests

Learn about these 5 key facts based on research featured in The Worldwide Market for Point-of-Care (POC) Diagnostic Tests, 9th Edition (published April 2022), a recent report by Kalorama Information Watch the one minute video below for insights and important facts regarding the POC diagnostic testing market. And as always, Kalorama Information offers even more […]

AACC Calls on Congress to Halt Legislation That Would Hinder Patient Access to Essential Medical Tests

WASHINGTON – AACC has sent comments to the U.S. Senate Health, Education, Labor & Pensions (HELP) Committee urging the committee not to include the VALID Act in its omnibus Food and Drug Administration (FDA) user fee legislation. VALID would limit the availability of vital laboratory-developed tests, decreasing patient access to life-saving diagnostic tools. View the comments […]

This Week in Cell and Gene Therapy: 14 New Developments to Know (May 23, 2022)

Pandemic Pushes Rx To OTC Switches

The U.S. Rx-to-OTC market has grown into a $13,807 million ($13.8 billion) market, according to 2021 estimates by leading medical market researcher Kalorama Information in the new report The Market for Rx-to-OTC Switches, 8th Edition. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, the FDA willingness […]

This week in Cell and Gene Therapy: 14 New Developments to Know (May 9, 2022)

There have been a number of recent developments in cell and gene therapy, as detailed in our bimonthly newsletter, Cell and Gene Therapy Business Outlook. The U.S. FDA has lifted clinical holds on two Phase III clinical studies evaluating gene therapies being developed by Pfizer, based in New York, NY. On April 28th, Pfizer announced […]